{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:49:23Z","timestamp":1791510563360,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Department of Clinical and Biological Sciences of Turin University","award":["RUSI_RILO_17"],"award-info":[{"award-number":["RUSI_RILO_17"]}]},{"name":"Department of Clinical and Biological Sciences of Turin University","award":["MORA_RILO_16"],"award-info":[{"award-number":["MORA_RILO_16"]}]},{"name":"Department of Clinical and Biological Sciences of Turin University","award":["GUEA_RILO_18"],"award-info":[{"award-number":["GUEA_RILO_18"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.numecd.2019.09.012","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T01:40:35Z","timestamp":1568684435000},"page":"282-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up"],"prefix":"10.1016","volume":"30","author":[{"given":"Cristina","family":"Barale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Frascaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Morotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Guerrasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cavalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2921-1763","authenticated-orcid":false,"given":"Isabella","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2019.09.012_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2019.09.012_bib2","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.2174\/13816128113199990313","article-title":"Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies","volume":"19","author":"Seidah","year":"2013","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.numecd.2019.09.012_bib3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacl.2015.01.001","article-title":"Understanding PCSK9 and anti-PCSK9 therapies","volume":"9","author":"McKenney","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2019.09.012_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2019.09.012_bib5","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2019.09.012_bib6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm1626","article-title":"Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype","volume":"13","author":"Podrez","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.numecd.2019.09.012_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/ATVBAHA.110.210252","article-title":"Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol","volume":"31","author":"Korporaal","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2019.09.012_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2019.09.012_bib9","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1345\/aph.1C013","article-title":"Aspirin resistance","volume":"36","author":"Howard","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.numecd.2019.09.012_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' health study","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2019.09.012_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF01696223","article-title":"Effects of long-term treatment with lovastatin on the clotting system and blood platelets","volume":"64","author":"Mayer","year":"1992","journal-title":"Ann Hematol"},{"key":"10.1016\/j.numecd.2019.09.012_bib12","first-page":"1305","article-title":"The anti-thrombotic effects of statins","volume":"33","author":"Kearney","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2019.09.012_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0021-9150(00)00397-X","article-title":"Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins","volume":"153","author":"Rauch","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2019.09.012_bib14","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2009.07.039","article-title":"Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction","volume":"104","author":"Santos","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2019.09.012_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0038-1676863","article-title":"PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention","volume":"119","author":"Paciullo","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.numecd.2019.09.012_bib16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2019.09.012_bib17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as a positive modulator of platelet activation","volume":"71","author":"Camera","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2019.09.012_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2004-822987","article-title":"Advanced method for the identification of patients with inherited hypercholesterolemia","volume":"4","author":"Defesche","year":"2004","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.numecd.2019.09.012_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosissup.2017.07.001","article-title":"LIPIGEN group, familial hypercholesterolemia: the Italian atherosclerosis society network (LIPIGEN)","volume":"29","author":"Averna","year":"2017","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.numecd.2019.09.012_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1055\/s-0029-1145254","article-title":"Clinical utility of the PFA-100","volume":"34","author":"Favaloro","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.numecd.2019.09.012_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001721-199901000-00004","article-title":"Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis","volume":"10","author":"Harrison","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.numecd.2019.09.012_bib22","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1055\/s-0039-1681061","article-title":"Transferrin saturation inversely correlates with platelet function","volume":"119","author":"Barale","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.numecd.2019.09.012_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2016.03.004","article-title":"Possible roles of platelet-derived microparticles in atherosclerosis","volume":"248","author":"Wang","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.numecd.2019.09.012_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2105\/AJPH.50.3_Pt_2.14","article-title":"The problem of elevated blood cholesterol","volume":"50","author":"Stamler","year":"1960","journal-title":"Am J Public Health Nation's Health"},{"key":"10.1016\/j.numecd.2019.09.012_bib25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.numecd.2016.05.006","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: present perspectives and future horizons","volume":"26","author":"Yadav","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2019.09.012_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.RES.72.4.737","article-title":"Altered vascular responses to platelets from hypercholesterolemic humans","volume":"72","author":"Kaul","year":"1993","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2019.09.012_bib27","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood-2016-01-631259","article-title":"Cholesterol in platelet biogenesis and activation","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.numecd.2019.09.012_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5551\/jat.25841","article-title":"The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease","volume":"22","author":"Li","year":"2015","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.numecd.2019.09.012_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2017.07.743","article-title":"Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation","volume":"70","author":"Pastori","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2019.09.012_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.hoc.2013.03.003","article-title":"Testing platelet function","volume":"27","author":"Harrison","year":"2013","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.numecd.2019.09.012_bib31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/09537104.2018.1478402","article-title":"Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes","volume":"30","author":"Harrison","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.numecd.2019.09.012_bib32","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.2174\/138161212803251943","article-title":"Clinical use of aspirin in ischemic heart disease: past, present and future","volume":"18","author":"De Caterina","year":"2012","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.numecd.2019.09.012_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2016.06.104","article-title":"A brief review on the mechanisms of aspirin resistance","volume":"220","author":"Du","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2019.09.012_bib34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH03-02-0111","article-title":"Platelet hyperactivity after statin treatment discontinuation","volume":"90","author":"Puccetti","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.numecd.2019.09.012_bib35","doi-asserted-by":"crossref","first-page":"6508709","DOI":"10.1155\/2018\/6508709","article-title":"Simvastatin effects on inflammation and platelet activation markers in hypercholesterolemia","volume":"2018","author":"Barale","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.numecd.2019.09.012_bib36","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood-2004-03-1108","article-title":"P-selectin binding to P-selectin glycoprotein ligand-1 induces an intermediate state of alphaMbeta2 activation and acts cooperatively with extracellular stimuli to support maximal adhesion of human neutrophils","volume":"104","author":"Ma","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.numecd.2019.09.012_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0735-1097(97)00129-0","article-title":"Platelet-dependent thrombin generation in patients with hyperlipidemia","volume":"30","author":"Aoki","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2019.09.012_bib38","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice","volume":"31","author":"Laufs","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.numecd.2019.09.012_bib39","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/ATVBAHA.106.128793","article-title":"Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase","volume":"27","author":"Haramaki","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2019.09.012_bib40","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2019.09.012_bib41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475319303515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475319303515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:10:27Z","timestamp":1760544627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475319303515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0939475319303515"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2019.09.012","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2019.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}